Bextra "not approvable" for migraine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's COX-2 inhibitor Bextra (valdecoxib) is "not approvable" for treatment of migraine as of August, Pfizer's Nov. 5 10-Q filing with the Securities & Exchange Commission states. Bextra faces another setback with the expected addition of a "black box" warning to labeling regarding skin reactions. "Revised labeling for the product…will likely include the addition of a black box," the SEC filing says. The firm's Oct. 15 "Dear Doctor" letter also includes a discussion of Bextra's cardiovascular safety profile. Data showing an apparent increased risk in CV events in two studies in high-risk surgery patients were presented at the American Heart Association meeting Nov. 9...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.